Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This research is being done to look at the effects of an experimental drug, ranibizumab, on a
condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due
to wet age-related macular degeneration.
A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% of the choroidal
neovascular lesion is occupied by blood under the retina. We want to find out if injections
of ranibizumab into the eye will help patients with this condition.